ALDEYRA THERAPEUTICS INC (ALDX) Stock News

USA - Nasdaq - NASDAQ:ALDX - US01438T1060 - Common Stock

5.48 USD

-0.11 (-1.97%)

Last: 11/28/2025, 8:12:22 PM

5.48 USD

0 (0%)

After Hours: 11/28/2025, 8:12:22 PM

Technical Analysis

Fundamental Analysis

Analyst Ratings

Earnings Estimates

ALDX Latest News, Press Relases and Analysis

All

Press Releases

16 days ago - By: Aldeyra Therapeutics, Inc.

Aldeyra Therapeutics Announces Expansion of RASP Platform to Include Central Nervous System Diseases and Provides Updates on Reproxalap at Research & Development Webcast

18 days ago - By: Aldeyra Therapeutics, Inc.

Aldeyra Therapeutics to Participate in the Jefferies Global Healthcare Conference in London

23 days ago - By: Aldeyra Therapeutics, Inc.

Aldeyra Therapeutics to Host Research & Development Update Webcast Event Scheduled for Thursday, November 13 at 8:00 a.m. ET

a month ago - By: Stocktwits

Aldeyra’s Experimental Drug Shows Promising Results In Mid-Stage Alcohol Hepatitis Trial

a month ago - By: Aldeyra Therapeutics, Inc.

Aldeyra Therapeutics Announces Positive Results from Phase 2 Clinical Trial in Alcohol-Associated Hepatitis, Focuses RASP Product Candidate Pipeline on Next-Generation Molecules

2 months ago - By: Benzinga - Mentions: CHRS ALEC BDTX

4 Biotechnology Stocks Lead Momentum Gains Amid Strong Technicals

2 months ago - By: Benzinga - Mentions: XBI APLT NGNE BCAX

4 Biotech Stocks Seeing Explosive Momentum Gains

3 months ago - By: Aldeyra Therapeutics, Inc.

Aldeyra Therapeutics to Participate in the H.C. Wainwright 27th Annual Global Investment Conference

3 months ago - By: Aldeyra Therapeutics, Inc.

Aldeyra Therapeutics Receives Orphan Designation from the European Medicines Agency for ADX-2191 for the Treatment of Primary Large B-Cell Lymphomas of Immune-Privileged Sites, including Primary Vitreoretinal Lymphoma

3 months ago - By: Yahoo Finance - Mentions: ABBV

JonesTrading Lifts Aldeyra Therapeutics, Inc. (ALDX) Price Target to $9

3 months ago - By: Aldeyra Therapeutics, Inc.

Aldeyra Therapeutics Receives Fast Track Designation for ADX‑2191 for the Treatment of Retinitis Pigmentosa

4 months ago - By: Aldeyra Therapeutics, Inc.

Aldeyra Therapeutics to Participate in the H.C. Wainwright 5th Annual Ophthalmology Virtual Conference

4 months ago - By: Aldeyra Therapeutics, Inc.

Aldeyra Therapeutics Receives Orphan Designation from the European Medicines Agency for ADX-2191 for the Treatment of Inherited Retinal Dystrophies including Retinitis Pigmentosa

5 months ago - By: Aldeyra Therapeutics, Inc.

Aldeyra Therapeutics Announces FDA Acceptance for Review of Reproxalap New Drug Application for the Treatment of Dry Eye Disease

5 months ago - By: Zacks Investment Research - Mentions: CPRX TBPH LRMR ZVRA

5 Small Drug Stocks to Buy Amid Trump's New Tariff Threats

5 months ago - By: Aldeyra Therapeutics, Inc.

Aldeyra Therapeutics Receives Special Protocol Assessment Agreement Letter from the U.S. Food and Drug Administration for ADX-2191 for the Treatment of Primary Vitreoretinal Lymphoma

6 months ago - By: Aldeyra Therapeutics, Inc.

Aldeyra Therapeutics Resubmits Reproxalap New Drug Application for the Treatment of Dry Eye Disease

6 months ago - By: Aldeyra Therapeutics, Inc.

Aldeyra Therapeutics to Participate in the 2025 Jefferies Global Healthcare Conference

7 months ago - By: Pomerantz LLP

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Aldeyra Therapeutics, Inc. - ALDX

7 months ago - By: Bragar Eagel & Squire - Mentions: OGN LSTR ICUI

Bragar Eagel & Squire, P.C. Is Investigating Organon, Aldeyra, Landstar, and ICU Medical and Encourages Investors to Contact the Firm

7 months ago - By: Pomerantz LLP

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Aldeyra Therapeutics, Inc. – ALDX

7 months ago - By: Pomerantz LLP

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Aldeyra Therapeutics, Inc. - ALDX

7 months ago - By: Pomerantz LLP

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Aldeyra Therapeutics, Inc. - ALDX

7 months ago - By: Bragar Eagel & Squire - Mentions: LSTR HOOD ICUI

Bragar Eagel & Squire, P.C. Is Investigating RobinHood, Aldeyra, Landstar, and ICU Medical and Encourages Investors to Contact the Firm

7 months ago - By: Pomerantz LLP

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Aldeyra Therapeutics, Inc. - ALDX

7 months ago - By: Aldeyra Therapeutics, Inc.

Aldeyra Therapeutics Achieves Primary Endpoint in Phase 3 Dry Eye Disease Chamber Trial of Reproxalap and Plans NDA Resubmission

7 months ago - By: Aldeyra Therapeutics, Inc.

Aldeyra Therapeutics Schedules Conference Call and Webcast to Announce Topline Results from Phase 3 Dry Eye Disease Clinical Trials of Reproxalap

7 months ago - By: Pomerantz LLP

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Aldeyra Therapeutics, Inc. - ALDX

7 months ago - By: Pomerantz LLP

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Aldeyra Therapeutics, Inc. - ALDX

7 months ago - By: Bragar Eagel & Squire - Mentions: TTGT

Bragar Eagel & Squire, P.C. Is Investigating TechTarget and Aldeyra and Encourages Investors to Contact the Firm

7 months ago - By: Pomerantz LLP

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Aldeyra Therapeutics, Inc. - ALDX

7 months ago - By: The Rosen Law Firm, P.A.

Rosen Law Firm Encourages Aldeyra Therapeutics, Inc. Investors with Losses in Excess of $100K to Inquire About Securities Class Action Investigation – ALDX

7 months ago - By: Pomerantz LLP

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Aldeyra Therapeutics, Inc. - ALDX

7 months ago - By: Pomerantz LLP

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Aldeyra Therapeutics, Inc. - ALDX

7 months ago - By: Bragar Eagel & Squire - Mentions: TTGT

Bragar Eagel & Squire, P.C. Is Investigating TechTarget and Aldeyra and Encourages Investors to Contact the Firm